It upregulates the expression of the RNAKL repressor Id2, which was also demonstrated in female patients with osteoporosis whose serum IL-27 levels were reduced along with decreased Egr2 expression (95), suggesting a potential new anti-osteoporosis treatment strategy. This evidence concerns the gene ID2 and osteoporosis.